BioSpace News Archive

Lemonex Inc., a biotechnology company pioneering messenger RNA and siRNA therapeutics based on a novel nanoparticle drug delivery system announced on the 14h of February that an Investigational New Drug application has been submitted to the Ministry of Food and Drug Safety for mRNA vaccine LEM-mR203 with its nano-drug delivery platform, DegradaBALL® on 20th of January.

Avanos Medical, Inc. will webcast its conference call discussing financial results and business highlights for the fourth quarter and full year 2022 on Tuesday, Feb. 21 at 9 a.m., ET.

Insulet Corporation announced it has acquired the assets of Automated Glucose Control LLC, a company in Palo Alto, California focused on developing and commercializing best in class automated insulin delivery technology.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced that the Company will report fourth quarter and fiscal year 2022 operating results after the close of the market on Tuesday, February 28, 2023.

Disc Medicine, Inc. (NASDAQ: IRON) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it has entered into a securities purchase agreement with certain investors resulting in an aggregate $62.5 million in gross proceeds through a registered direct offering.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided multiple clinical trial and regulatory updates for its lead compound sebetralstat, as a potential oral on-demand therapy for HAE attacks.

InDex Pharmaceuticals Holding AB (publ) is today making a presentation with CEO Jenny Sundqvist available in light of the press release issued January 27, 2023 regarding the updated timeline of the CONCLUDE program.

Gritstone bio, Inc. announced that it has entered into a clinical trial agreement with the National Cancer Institute, an institute of the National Institutes of Health, to evaluate an autologous T cell therapy expressing a T cell receptor targeting mutated KRAS in combination with Gritstone’s KRAS-directed vaccine candidate, SLATE-KRAS, in a Phase 1 study.

Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, March 1, 2023 at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2022.

Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal third quarter ended December 31, 2022.